FDA accepts United Therapeutics ralinepag NDA
Analysis based on 10 articles · First reported Aug 24, 2026 · Last updated Aug 24, 2026
The FDA acceptance of the NDA for ralinepag is a positive regulatory milestone for United Therapeutics, potentially strengthening its position in the PAH treatment market. The news is likely to boost investor sentiment for United Therapeutics, while the FDA's review process will be closely watched by the market.
United Therapeutics announced that the U.S. United States — Food and Drug Administration has accepted its New Drug Application for ralinepag, an investigational once-daily oral prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. The FDA set a Prescription Drug User Fee Act target action date of June 24, 2027. The filing is based on the phase 3 ADVANCE OUTCOMES study, which met its primary endpoint with a statistically significant 55% reduction in risk of clinical worsening versus placebo in predominantly pre-treated PAH patients. Ralinepag also achieved statistical significance on key secondary endpoints, including reductions in NT-proBNP and improvements in exercise capacity. The safety profile was consistent with known prostacyclin-related adverse events. The data were presented at the American Thoracic Society annual meeting and published in The Lancet. Ralinepag has not yet been approved by the FDA and remains investigational.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard